2024-03-15 17:22:51
The rVSVΔG-ZEBOV-GP (Ervebo) vaccine not only reduces the risk of Ebola virus infection, but it also halves mortality rates. This is the result of a study published in The Lancet Infectious Disease.
Rebecca Coulborn, an epidemiologist at Epicenter in Paris, France, and colleagues analyzed data collected during the tenth Ebola outbreak in the Democratic Republic of Congo. Their analysis found that among 2,279 patients with confirmed Ebola who were admitted to an Ebola health facility between July 27, 2018 and April 27, 2020, the mortality risk was 56% among unvaccinated patients. In vaccinated patients, on the other hand, it was only 25%. The reduction in mortality applied to all patients, regardless of age and gender.
The study was funded by Doctors Without Borders. For data collection, Epicenter, the epidemiological division of Doctors Without Borders, collaborated with the National Institute of Biomedical Research and the Ministry of Health of the Democratic Republic of Congo.
The study authors focused on the Ervebo vaccine, whose use once morest the Zaire Ebola virus is authorized in the European Union, in the United States and some African countries, among others. It is the only Ebola vaccine currently recommended for use in outbreaks. Ervebo is administered intramuscularly in a single dose and is approved for adults aged 18 and older.
The vaccine is primarily recommended for ring vaccination of people at high risk of infection during an epidemic. In vaccine studies, the vaccine has been used for ring vaccinations among contacts of cases diagnosed since the end of the Ebola epidemic in West Africa in 2014 and 2015 and since 2018 in the Democratic Republic of Congo.
The preliminary estimated vaccine effectiveness 10 days following vaccination is 97.5% to 100%. The duration of protection is unknown. People who became ill despite vaccination generally experienced a milder course of illness.
Although vaccination should be given as early as possible during Ebola outbreaks, results from the Epicenter study showed that the vaccine still protects once morest the risk of infection, even when administered following exposure to the virus. .
“Vaccination following exposure to an Ebola-infected person, even when administered shortly before symptoms appear, still provides significant protection once morest death”summarized Rebecca Coulborn in a press release from Doctors Without Borders. “The reduction in this risk is added to that due to the specific treatment of Ebola, regardless of the time before treatment. »
This article was translated from Medscape German using multiple editorial tools, including AI, in the process. The content has been reviewed by the editorial staff of Medscape.fr before publication.
1710525123
#Ebola #vaccine #saves #lives #exposure #virus
